ライフサイエンスコーパス: transcriptase

1 s C virus (HCV) polymerase and HIV-1 reverse transcriptase.

2 AN in the absence of HIV protease or reverse transcriptase.

3 RNA-binding domain of the telomerase reverse transcriptase.

4 antagonized by inhibitors of the L1 reverse transcriptase.

5 using a thermostable group II intron reverse transcriptase.

6 otide incorporation catalyzed by HIV reverse transcriptase.

7 ng RNA is the core of the telomerase reverse transcriptase.

8 ey murine leukemia virus (MMLV)-type reverse transcriptases.

9 y catalyzed by wild-type and variant reverse transcriptases.

10 an DNA polymerases relative to viral reverse transcriptases.

11 a predicted DGR system, including a reverse transcriptase, a template repeat and one (or more) varia

12 The effect of mutations on virus reverse-transcriptase activity and infectiousness was analyzed i

13 te this by combined inhibition of L1 reverse transcriptase activity and the Chk2-dependent DNA damage

14 Licensed antivirals target the HBV reverse transcriptase activity but fail to eliminate cccDNA, whi

15 al family A polymerase with inherent reverse transcriptase activity for use in RT-PCR.

16 RNA strand of an RNA:DNA hybrid and reverse transcriptase activity on a DNA-primed RNA template.

17 d pharmacologically inhibiting viral reverse transcriptase activity prevents degenerative phenotypes

18 ated Tbk1 and, importantly, blocking reverse transcriptase activity suppressed the expression of inte

19 d Mn(2+)-dependent virion-associated reverse transcriptase activity typical of a gammaretrovirus.

20 thermostability and display elevated reverse transcriptase activity.

21 e the platform, we evolved the HIV-1 reverse transcriptase against N(1)-methyladenosine (m(1)A).

22 endent DNA polymerase activity among reverse transcriptases, an observation consistent with structura

23 with genes encoding human telomerase reverse transcriptase and doxycycline-inducible MyoD, generate d

24 -generation sequencing assay for the reverse transcriptase and gp41 genes.

25 ted HIV in combination with clinical reverse transcriptase and integrase inhibitors.

26 reversibly linked combination of HIV reverse transcriptase and protease inhibitors.

27 A targets using polymerase with both reverse-transcriptase and strand displacement activities to obta

28 Mutations in the telomerase reverse transcriptase and telomerase RNA component genes have be

29 inally biotinylated human telomerase reverse transcriptase and using a newly developed method to coun

30 hree drug-target proteins: protease, reverse transcriptase, and integrase; a comparative analysis rev

31 ns challenging as retroviral-derived reverse transcriptases are often not sufficiently thermostable t

32 s, consistent with blockage of viral reverse transcriptase at gRNA branch points.

33 h may signal intrinsic difference of reverse transcriptase between these viral species or different h

34 d crystal structures showed that HIV reverse transcriptase binds only two metal ions prior to incorpo

35 d G-rich sequences, ahead of diverse reverse transcriptases can be strong stimulators for slippage at

36 nced, specifically due to telomerase reverse transcriptase component (TERT) down-regulation, immediat

37 ectors, which vary either by using a reverse transcriptase-dependent diversity-generating system or t

38 The optimal evolved reverse transcriptase enabled detection of well-characterized m(

39 ave also been created in primates by reverse transcriptase-encoding elements like LINE-1 or endogenou

40 rised of an RNA component, TLC1, the reverse transcriptase, Est2, and regulatory subunits, including

41 This work develops and validates the reverse transcriptase evolution platform, and provides new tools

42 as well as the spatial separation of reverse transcriptase from the viral genome during early steps o

43 hich are CRISPR-Cas9 nickase (H840A)-reverse transcriptase fusions programmed with prime editing guid

44 Since 2006, HIV protease and reverse transcriptase gene (pol) sequences from drug resistance

45 ined by analyzing 155,462 single HIV reverse transcriptase gene (RT) and 6,985 vif sequences from 33

46 ons, such as those in the telomerase reverse transcriptase gene (TERT) promoter, activate gene expres

47 how that at the same shift motif HIV reverse transcriptase generates -1 and +1 indels with their rati

48 We obtained 58 protease/reverse transcriptase genotypes.

49 tional TNA aptamers that bind to HIV reverse transcriptase (HIV RT) with K(D)'s of ~0.4-4.0 nM.

50 s using human immunodeficiency virus reverse transcriptase (HIV-RT) and three DNA-polymerases showed

51 telomerase complex that contains the reverse transcriptase hTERT and RNA template TERC/hTR.

52 l activation of the human telomerase reverse transcriptase (hTERT) gene, which remains repressed in a

53 and techniques based on quantitative reverse transcriptase in real time, we evaluated 60 melanoma cel

54 nucleoprotein complex that acts as a reverse transcriptase in the elongation of telomeres.

55 We also show that hpol eta acts as a reverse transcriptase in the presence of damaged ribonucleotide

56 h POT1/TRF2 and via human telomerase reverse transcriptase inhibition through JNK activation.

57 article incorporation, inhibition of reverse transcriptase inhibition, and DNA cytidine deamination.I

58 0.71 [0.61-0.82]) and non-nucleoside reverse transcriptase inhibitor (0.68 [0.51-0.90]) or integrase

59 inhibitor (NRTI) plus nonnucleoside reverse-transcriptase inhibitor (43%), NRTI plus integrase stran

60 or drug resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) at codons Lys103Asn, Tyr

61 oviral therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two NRTIs has faile

62 y virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are

63 actors associated with nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance.

64 virine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active against wild-

65 human immunodeficiency virus (HIV)-1 reverse transcriptase inhibitor (NNRTI), was safe and effective

66 e inhibitor (PI)-, and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART between Januar

67 rapy on a TDF/XTC plus nonnucleoside reverse-transcriptase inhibitor (NNRTI)-containing regimen.

68 e 1 (HIV-1) by a novel nonnucleoside reverse transcriptase inhibitor (NNRTI).

69 renz, presence of both nonnucleoside reverse transcriptase inhibitor (NNRTI)/nucleoside reverse trans

70 emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or efavirenz)

71 the highly water-soluble nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (FTC), and

72 ) for HIV patients is the nucleoside reverse transcriptase inhibitor (NRTI) is tenofovir.

73 regimens were nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI) plus nonnucleoside revers

74 cally administered nucleoside analog reverse transcriptase inhibitor azidothymidine (AZT).

75 Remarkably, reverse transcriptase inhibitor AZT-treated Chk2 mutant oocytes

76 ation of LysRS, but treatment with a reverse transcriptase inhibitor does not, suggesting that the tr

77 For nucleotide reverse transcriptase inhibitor DRMs, sensitivity and specificit

78 For non-nucleotide reverse transcriptase inhibitor DRMs, sensitivity and specificit

79 older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identified in sub

80 ent of aged mice with the nucleoside reverse transcriptase inhibitor lamivudine downregulated IFN-I a

81 HIV-1-infected cells treated with a reverse-transcriptase inhibitor or with heat-inactivated HIV-1.

82 riptase inhibitor (NNRTI)/nucleoside reverse transcriptase inhibitor PDR vs no PDR was associated wit

83 /mL, and 79% were on a nonnucleoside reverse transcriptase inhibitor regimen.

84 of eight had archived non-nucleoside reverse transcriptase inhibitor resistance-associated mutations

85 ing formulation of the nonnucleoside reverse transcriptase inhibitor rilpivirine (RPV LA) has been pr

86 (PI) lopinavir (LPV) and nucleoside reverse transcriptase inhibitor tenofovir alafenamide (TAF) was

87 RT) containing the modern nucleoside reverse transcriptase inhibitor tenofovir.

88 oravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has shown non-inferior effi

89 centration and background nucleoside reverse transcriptase inhibitor therapy, to doravirine (100 mg p

90 ividuals on first-line nonnucleoside reverse transcriptase inhibitor-based ART regimens.

91 hich support its use as a nucleoside reverse transcriptase inhibitor-sparing and protease inhibitor-s

92 st-generation nonnucleoside analogue reverse transcriptase inhibitor.

93 R was dolutegravir plus 2 nucleoside reverse transcriptase inhibitors (46.9%).

94 imens based on either Non-Nucleoside Reverse Transcriptase Inhibitors (EFV) or ritonavir-boosted Prot

95 ir, atazanavir), and 2 nonnucleoside reverse transcriptase inhibitors (nevirapine, efavirenz).

96 are moving away from non-nucleoside reverse transcriptase inhibitors (NNRTI) and transitioning to do

97 ion (SDRM), including 3 nonnucleosidereverse transcriptase inhibitors (NNRTI) SDRMs (1 K101E, 2 K103N

98 rotease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTI), with dolutegravir and

99 osted ARVs (30%), and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (32%) based regimens.

100 ence of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) reached 45% (95% CI: 2

101 esistance of HIV-1 to non-nucleoside reverse transcriptase inhibitors (NNRTIs) threatens the success

102 ed major mutations to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse tr

103 ug resistance (TDR) to nonnucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse tr

104 protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs), with dolutegravir and

105 Nucleoside reverse-transcriptase inhibitors (NRTI), drugs approved to treat

106 Prior exposure to both nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs and confi

107 Nucleoside reverse transcriptase inhibitors (NRTIs) are widely used as anti

108 OPTIONS trial showed that nucleoside reverse transcriptase inhibitors (NRTIs) can be safely omitted f

109 osted lopinavir, plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults in whom previ

110 otease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination

111 Nucleoside reverse transcriptase inhibitors (NRTIs) were the first drugs us

112 Nucleoside reverse transcriptase inhibitors (NRTIs) with L-stereochemistry

113 tase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease inhibitor

114 tase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease inhibitor

115 be a major substrate for TREX1, and reverse transcriptase inhibitors (RTIs) were proposed as a thera

116 rts B (B1, best available nucleoside reverse transcriptase inhibitors [NRTIs] plus ritonavir-boosted

117 Nine nucleoside reverse-transcriptase inhibitors and 37 nucleoside/heterocycle a

118 V, emergent resistance to nucleoside reverse transcriptase inhibitors and nonnucleoside reverse trans

119 ion of thymidine analogue nucleoside reverse transcriptase inhibitors as the cause of lipoatrophy led

120 at telomerase can add the nucleotide reverse transcriptase inhibitors ddITP and AZT-TP to the telomer

121 acaques with protease, integrase, or reverse transcriptase inhibitors for 1 to 2 or for 5 to 6 weeks

122 EFV; 600 mg daily) with 2 nucleoside reverse transcriptase inhibitors for 52 weeks.

123 received ineffective non-nucleoside reverse transcriptase inhibitors for PMTCT.

124 The antiviral activity of nucleoside reverse transcriptase inhibitors is often hampered by insufficie

125 ce to the co-administered nucleoside reverse transcriptase inhibitors might reduce effectiveness and

126 ponses to cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-boosted protea

127 regimen consisted of two nucleoside reverse transcriptase inhibitors plus nevirapine dosed at 6 mg/k

128 riptase inhibitors and nonnucleoside reverse transcriptase inhibitors).

129 Among nucleoside/nucleotide reverse transcriptase inhibitors, tenofovir alafenamide was asso

130 evidence of resistance to nucleoside reverse transcriptase inhibitors.

131 potency for all drug classes except reverse transcriptase inhibitors.

132 with the same backbone of Nucleoside Reverse Transcriptase Inhibitors.

133 all mutations were to nonnucleoside reverse transcriptase inhibitors.

134 ith investigator-selected nucleoside reverse transcriptase inhibitors: emtricitabine and tenofovir di

135 Structural studies of reverse transcriptase initiation complexes (RTICs) have revealed

136 st that hpol eta is one of the major reverse transcriptases involved in physiological processes in hu

137 is a hallmark of ageing, and that L1 reverse transcriptase is a relevant target for the treatment of

138 Lentiviral replication mediated by reverse transcriptase is considered to be highly error prone, le

139 B69 DNA polymerase (Arg-482) and HIV reverse transcriptase (Lys-65) were previously observed to inhib

140 e introns, and intron loss is likely reverse transcriptase mediated.

141 arge A3G oligomers could block HIV-1 reverse transcriptase-mediated DNA synthesis, thereby inhibiting

142 Here, we uncovered that telomerase reverse transcriptase null (Tert(-/-)) mESCs exhibit genome-wide

143 binding between the protein subunit reverse transcriptase of the telomerase and its nucleic acid sub

144 erium that lacks either a standalone reverse transcriptase or its fusion to spacer integrase Cas1.

145 virus (HBV) encodes a multifunction reverse transcriptase or polymerase (P), which is composed of se

146 PR/Cas9 knockout of human telomerase reverse transcriptase or treatment with the telomerase-mediated

147 41), gag (capsid, p24; matrix, p17), reverse transcriptase (p66/51), and integrase (p31) were seriall

148 Quantitative reverse-transcriptase PCR (qRT-PCR) analysis showed that these 5

149 Using an MDV genome quantitative reverse transcriptase PCR (qRT-PCR) array and chromatin immunopr

150 s using flow cytometry, quantitative reverse-transcriptase PCR (qRT-PCR), and RNA-Seq for PD-1 expres

151 xpression changes using quantitative reverse-transcriptase PCR (qRT-PCR), immunofluorescence, and Lum

152 , were EBOV positive by quantitative reverse transcriptase PCR (qRT-PCR).

153 says, such as conventional real-time reverse transcriptase PCR (rRT-PCR), detect total RNA in a sampl

154 copies/ml) but can be quantified by reverse transcriptase PCR (RT-PCR) assays with single-copy sensi

155 mptom onset or post-initial positive reverse transcriptase PCR (RT-PCR) result were 92.9% (78/84), 88

156 rol) and a prototype, and SARS-CoV-2 reverse transcriptase PCR (RT-PCR) results were compared.

157 A real-time reverse transcriptase PCR (RT-PCR) screening revealed that 8 tis

158 veloped test (modified CDC 2019-nCoV reverse transcriptase PCR [RT-PCR] assay with RNA extraction by

159 A real-time quantitative reverse transcriptase PCR assay with single-copy sensitivity tar

160 This was confirmed by quantitative reverse transcriptase PCR in infected and uninfected gastric muc

161 ogy, immunoassays, gel-based PCR and reverse transcriptase PCR, and quantitative real-time PCR (qPCR)

162 vels from tissues are measured using reverse transcriptase PCR, microarray analysis or high-throughpu

163 ) detection of T. pallidum in CSF by reverse transcriptase PCR, or (iii) new vision loss or hearing l

164 polymerase chain reaction (PCR) and reverse transcriptase PCR.

165 polymerase chain reaction (PCR) and reverse transcriptase PCR.

166 quencing, and quantitative real-time reverse transcriptase-PCR of tissue biopsy samples.

167 luated with microarray profiling and reverse transcriptase-PCR.

168 ermined using real-time quantitative reverse transcriptase-PCR.

169 nded redesign of the WHO-recommended reverse transcriptase PCRs (RT-PCRs).

170 of life were tested by quantitative reverse transcriptase polymerase chain reaction (PCR) and/or IgM

171 for SARS-CoV-2, including real-time reverse-transcriptase polymerase chain reaction (rRT-PCR), viral

172 RS-CoV-2 culture with the results of reverse transcriptase polymerase chain reaction (RT-PCR) and oth

173 coronavirus 2 (SARS-CoV-2) based on reverse transcriptase polymerase chain reaction (RT-PCR) are bei

174 h perforated peptic ulcer, real time reverse transcriptase polymerase chain reaction (RT-PCR) examina

175 VID-19), a SARS-CoV-2 virus-specific reverse transcriptase polymerase chain reaction (RT-PCR) test is

176 ith history of a positive SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) test re

177 owever, they are less sensitive than reverse transcriptase polymerase chain reaction (RT-PCR) tests.

178 coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibo

179 ecimens were tested for influenza by reverse-transcriptase polymerase chain reaction (RT-PCR).

180 ression pattern of several genes via reverse transcriptase polymerase chain reaction (RT-PCR).

181 Quantitative reverse-transcriptase polymerase chain reaction analysis of 6 sc

182 ere tested for influenza by means of reverse-transcriptase polymerase chain reaction and were sequenc

183 Quantitative reverse transcriptase polymerase chain reaction and Western blot

184 BCR-ABL transcript in a quantitative reverse transcriptase polymerase chain reaction assay confirmed

185 haryngeal or lower respiratory tract reverse transcriptase polymerase chain reaction assays, (b) seve

186 l 2020, all but 5 patients (96%) had reverse transcriptase polymerase chain reaction based COVID-19 t

187 he CABG surgery and were analyzed by reverse transcriptase polymerase chain reaction for periodontal

188 ffecting splicing as demonstrated by reverse transcriptase polymerase chain reaction performed in mus

189 tudy characterizes the prevalence of reverse-transcriptase polymerase chain reaction results positive

190 Both reverse transcriptase polymerase chain reaction tests and rapid

191 h COVID-19 confirmation on real-time reverse transcriptase polymerase chain reaction were identified.

192 carried out by immunohistochemistry, reverse-transcriptase polymerase chain reaction, and genotyping.

193 lot) and messenger RNA (quantitative reverse transcriptase polymerase chain reaction, RNAscope) conte

194 Real-time reverse transcriptase polymerase chain reaction-based assays per

195 ded in our study (n=38 patients with reverse transcriptase polymerase chain reaction-confirmed COVID-

196 e values of chest CT versus those of reverse transcriptase polymerase chain reaction.

197 onfirmed dengue by serotype-specific reverse-transcriptase polymerase chain reaction.

198 had subsequent proof of COVID-19 by reverse-transcriptase polymerase chain reaction.

199 d mRNA expression using quantitative reverse transcriptase polymerase chain reaction.

200 V-2 infection confirmed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay o

201 Using data from 170 reverse transcriptase-polymerase chain reaction (RT-PCR)-confirm

202 combined with quantitative real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) to sig

203 analyzed by multiplexed quantitative reverse transcriptase-polymerase chain reaction after the dietar

204 Specific real-time reverse transcriptase-polymerase chain reaction targeting 3 SARS

205 was also quantified by quantitative reverse transcriptase-polymerase chain reaction, and DNA methyla

206 Quantitative reverse transcriptase-polymerase chain reaction, Western blot, a

207 d for RSV infections using real-time reverse transcriptase-polymerase chain reaction.

208 insulin resistance were evaluated by reverse transcriptase-polymerase chain reaction.

209 D-loop were measured by quantitative reverse transcriptase-polymerase chain reaction.

210 subgroup of these women on real-time reverse-transcriptase-polymerase-chain-reaction (rRT-PCR) assay.

211 2485 (4%) were confirmed by means of reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay.

212 sitive result for Ebola virus RNA on reverse-transcriptase-polymerase-chain-reaction assay were enrol

213 tory programs that were dependent on reverse transcriptase produced from LINE1s.

214 endonuclease fused to an engineered reverse transcriptase, programmed with a prime editing guide RNA

215 ymes required for virus replication: reverse transcriptase, protease, and integrase.

216 x, and mRNA levels were assessed via reverse transcriptase quantitative PCR (qRT-PCR).

217 Reverse transcriptase quantitative PCR (RT-qPCR) confirmed the p

218 A (tmRNA), pre-16S rRNA, and rpoB by reverse transcriptase quantitative PCR (RT-qPCR) showed minimal

219 ate confirmed by immunofluorescence, reverse transcriptase quantitative PCR (RT-qPCR), and NGS.

220 arison of virus titration results to reverse transcriptase quantitative PCR and measurement of fluore

221 Cytokine expression was examined by reverse-transcriptase quantitative PCR, intracellular flow cytom

222 s were assessed using microarray and reverse transcriptase quantitative PCR.

223 ling using high throughput stem-loop reverse-transcriptase quantitative polymerase chain reaction and

224 ein translation were confirmed using reverse transcriptase quantitative polymerase chain reaction.

225 licly available expression data, and reverse transcriptase quantitative polymerase chain reaction.

226 Reverse-transcriptase-quantitative PCR (RT-Q-PCR) and RT-PCR amp

227 s were confirmed positive for YFV by reverse transcriptase-quantitative polymerase chain reaction (RT

228 7, RANKL, and OPG) was determined by reverse transcriptase - real-time polymerase chain reaction (RT-

229 V-1 env (C2-V3), gag (p24), and pol (reverse transcriptase) regions amplified from cell-free HIV RNA

230 nes TERT and separates it from other reverse transcriptases remains a subject of debate.

231 Telomerase is the essential reverse transcriptase required for linear chromosome maintenance

232 g Chlamydomonas and human telomerase reverse transcriptase-retinal pigment epithelial cell line, we s

233 o the Tribolium castaneum telomerase reverse transcriptase reveals an atypical interaction, in which

234 de analogs capable of inhibiting the reverse transcriptase (RT) activity of HIV and hepatitis B virus

235 ain SGR uses an RNA intermediate and reverse transcriptase (RT) activity, which are characteristics s

236 mpetitively bind the RNA template or reverse transcriptase (RT) and act as a roadblock to DNA polymer

237 mmunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and protease sequences were obtained

238 ates act as dNTP analogues and HIV-1 reverse transcriptase (RT) catalytically incorporates the TFV pa

239 HIV type I (HIV-1) reverse transcriptase (RT) catalyzes the conversion of viral RNA

240 Reverse transcriptase (RT) enzymes are indispensable tools for i

241 RNA aptamers that bind HIV-1 reverse transcriptase (RT) inhibit RT in enzymatic and viral rep

242 iven by an increase in nonnucleoside reverse-transcriptase (RT) inhibitor (NNRTI) resistance mutation

243 ained naive or were treated with the reverse transcriptase (RT) inhibitor lamivudine (3TC).

244 man CD4(+) T cells failed to mount a reverse transcriptase (RT) inhibitor-sensitive immune response f

245 Nucleoside analogue reverse transcriptase (RT) inhibitors, such as entecavir (ETV) a

246 HIV-1 reverse transcriptase (RT) is an essential enzyme, targeting hal

247 112D and M230I, were selected in the reverse transcriptase (RT) of human immunodeficiency virus type

248 HIV-1 reverse transcriptase (RT) possesses both DNA polymerase activit

249 NA library steps are replaced with a reverse-transcriptase (RT) reaction that adds a unique molecular

250 viral RNA genomic template in which reverse transcriptase (RT) stalls.

251 -switching oligo (TSO), allowing the reverse transcriptase (RT) to switch templates and continue copy

252 Deep sequencing of HIV reverse transcriptase (RT) was performed (Roche/454), and the se

253 hrough a virtual screening using HIV-reverse transcriptase (RT), adenylate/guanylate kinase, and huma

254 d subtyped in the gag, protease (PR)-reverse transcriptase (RT), integrase (IN) and/or envelope (env)

255 Human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated ribonuclease H (RNase H) r

256 s: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (modified CDC) a

257 odified version of the CDC Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel and two commerci

258 in respiratory samples by Real-time Reverse Transcriptase (RT)-PCR or other molecular methods.

259 cleus, we opted for developing HIV-1 reverse transcriptase (RT)-specific 2'-deoxynucleoside analogs t

260 A enhances the processivity of HIV-1 reverse transcriptase (RT).

261 he essential viral polymerase, HIV-1 reverse transcriptase (RT).

262 The reverse transcriptases (RTs) encoded by mobile group II introns

263 Bacterial group II intron reverse transcriptases (RTs) function in both intron mobility an

264 The ability of reverse transcriptases (RTs) to synthesize a complementary DNA f

265 report here crystal structures of a reverse transcriptase RTX, which was evolved in vitro from the B

266 we used thermostable group II intron reverse transcriptase sequencing (TGIRT-seq) combined with peak

267 sed of a dedicated RNA subunit and a reverse transcriptase (telomerase reverse transcriptase [TERT]).

268 uently mutated genes were telomerase reverse transcriptase (TERT) (58.1%), catenin beta 1 (CTNNB1) (3

269 tains a catalytic core of telomerase reverse transcriptase (TERT) and telomerase RNA (TER).

270 ons in the genes encoding telomerase reverse transcriptase (TERT) and telomerase's RNA components as

271 ore of which includes the telomerase reverse transcriptase (TERT) and the non-coding human telomerase

272 evident up-regulation of telomerase reverse-transcriptase (TERT) expression was detected in mTert (+

273 ified neuroblastomas with telomerase reverse transcriptase (TERT) gene overexpression and coordinated

274 d these observations into telomerase reverse transcriptase (TERT) immortalized oral keratinocytes (NO

275 of promoter mutations in telomerase reverse transcriptase (TERT) in blood leukocytes of approximatel

276 Because telomerase reverse transcriptase (TERT) is usually the limiting component f

277 Similarly, telomerase reverse transcriptase (tert) mutant zebrafish have premature sho

278 es of Tribolium castaneum telomerase reverse transcriptase (TERT) throughout its catalytic cycle and

279 e same genes, such as the telomerase reverse transcriptase (TERT), but through differential effects o

280 35 cancers, 73% expressed telomerase reverse transcriptase (TERT), which was associated with TERT poi

281 riptional upregulation of telomerase reverse transcriptase (TERT).

282 telomerase RNA (TER) and telomerase reverse transcriptase (TERT).

283 a reverse transcriptase (telomerase reverse transcriptase [TERT]).

284 Thermostable group II intron reverse transcriptases (TGIRTs) with high fidelity and processiv

285 Telomerase is a specialized reverse transcriptase that adds GGTTAG repeats to chromosome end

286 Telomerase, a unique reverse transcriptase that specifically extends the ends of line

287 d evolution that rapidly selects for reverse transcriptases that install mutations at sites of a give

288 While some Type III systems encode a reverse transcriptase to acquire spacers from foreign transcript

289 virus that utilizes a virus-encoded reverse transcriptase to convert an RNA intermediate, termed pre

290 enetic elements that use error-prone reverse transcriptases to generate vast sequence variants in spe

291 ts, retrons, that employ specialized reverse transcriptases to produce noncoding intracellular DNAs.

292 While c-TDR requires reverse transcriptase, translesion DNA polymerase zeta (Pol zeta

293 and MK-8591) is a unique nucleoside reverse transcriptase translocation inhibitor in clinical develo

294 2'-deoxyadenosine [EFdA]) is a novel reverse transcriptase-translocation inhibitor.

295 s encoding HIV (lacking protease and reverse transcriptase), Vpr, or vector control.

296 cally augmented Thumb domain, and of reverse transcriptase, which extends its Thumb with the RNase H

297 terative rounds of selection yielded reverse transcriptases with both robust read-through and high mu

298 In the presence of other reverse transcriptases with higher fidelity like AMV-RT, the met

299 ted a combination of four commercial reverse transcriptases with two priming techniques to faithfully

300 ts, and they were substrates for HIV-reverse transcriptase without being substrates for DNA-polymeras